Beijing Foyou Pharma (601089.SH): The clinical trial of FY103 injection has been approved. Currently, there are no similar products with the same target on the market both domestically and internationally.

Beijing Foyou Pharma (601089.SH) issued an announcement recently that the company has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for FY103 injection, and will soon start clinical trials. FY103 injection is a Class 1 innovative drug independently developed by the company, suitable for the treatment of hypertension, administered by subcutaneous injection. Currently, there are no similar products on the market with the same target both domestically and internationally. As of now, the total research and development investment in FY103 injection related projects is approximately RMB 29.49 million (unaudited).